ONYX-015: ONXX said it will not expand its ongoing Phase III trial or start other pivotal trials of ONYX-015 until it can manufacture additional batches of the

Onyx Pharmaceuticals Inc. (ONXX), Richmond, Calif. Product: ONYX-015 Business: Cancer Therapeutic category: Cytotoxic Target: Cells lacking p53 Description: Engineered adenovirus lacking the E1B 55-kD...